Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.74% | 306.72 | 0.0% | $5256.57m | |
| BNTX | BioNTech SE | 3.17% | 344.06 | 0.0% | $1596.83m | |
| NVAX | Novavax, Inc. | -0.92% | 160.48 | 78.2% | $831.00m | |
| AMGN | Amgen, Inc. | 0.63% | 202.44 | 1.4% | $596.39m | |
| GILD | Gilead Sciences, Inc. | -0.16% | 69.56 | 1.0% | $505.86m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.18% | 635.16 | 2.7% | $472.48m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.31% | 203.81 | 1.9% | $464.56m | |
| LGVN | Longeveron Inc. | 11.78% | 20.12 | 0.0% | $429.77m | |
| ILMN | Illumina, Inc. | -2.85% | 347.28 | 3.3% | $324.28m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -4.21% | 4.10 | 0.7% | $286.61m | |
| BIIB | Biogen, Inc. | -2.01% | 223.92 | 1.8% | $276.52m | |
| INCY | Incyte Corp. | -1.28% | 65.78 | 2.4% | $150.25m | |
| SGEN | Seagen Inc. | -5.00% | 150.74 | 5.8% | $149.09m | |
| EXAS | EXACT Sciences Corp. | -4.94% | 76.59 | 18.0% | $140.15m | |
| OCGN | Ocugen, Inc. | -8.72% | 5.76 | 0.0% | $139.18m |
Company Profile
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.